Tarlatamab-Dlle. 1 mg, 10 mg Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 1 mg, 10 mg
Reference Brands: Imdelltra (USA), Imdylltra (EU/UK)
Category: Oncology Cancer Care
Tarlatamab-dlle is a bispecific T-cell engager (BiTE) antibody that binds DLL3 on small cell lung cancer cells and CD3 on T cells, enabling targeted immune killing of tumor cells. It is approved for adults with extensive-stage small cell lung cancer who have progressed after platinum-based chemotherapy. It has shown meaningful response rates and durable clinical benefit in resistant disease. The treatment is given by step-up intravenous infusion to reduce the risk of cytokine release syndrome. Patients are monitored closely for immune-related reactions and neurological side effects.
Tarlatamab-Dlle. — third party manufacturing & bulk supply
Tarlatamab-Dlle. 1 mg, 10 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Indicative minimum order quantity
Tarlatamab-Dlle. is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Tarlatamab-Dlle. listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Tarlatamab-Dlle. →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Tarlatamab-dlle is used for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in adults who have disease progression after platinum-based chemotherapy.
It is made from a bispecific T-cell engager (BiTE) antibody construct that binds to DLL3 on tumor cells and CD3 on T-cells to trigger targeted immune-mediated killing.
The trade name is Imdelltra.
It is manufactured and marketed by Amgen Inc.
The generic name is tarlatamab-dlle.
The brand name is Imdelltra.
It is manufactured by Amgen at its biologics production facilities in the United States.
Related Products
Fruquin 5 Mg (Fruquintinib)
Strength:
5 Mg
Form: Capsules
Reference Brands: Everest Bangladesh altd.
View Details
Vorinostat
Strength:
100 mg
Form: Capsules
Reference Brands: Zolinza (USA/EU), Vornat (India)
View Details
Panobinostat Lactate
Strength:
10 mg, 15 mg, 20 mg
Form: Capsules
Reference Brands: Farydak (USA/EU),
View Details
Gilteritinib
Strength:
40 mg
Form: Tablets
Reference Brands: Xospata (USA/India), LuciGil (Asia)
View DetailsQuick Response Guaranteed | Verified Suppliers
